Ocular cicatricial pemphigoid is an uncommon but severe and potentially blinding systemic disease. It shares
Clinically, cicatrising conjunctivitis may range from asymptomatic subtarsal or canthal fibrosis to a complete obliteration of the fornices with total keratinisation of the ocular surface. 
BULLOUS SKIN DISEASES
All of the bullous skin diseases may be associated with cicatricial conjunctival changes but they are uncommon, mild and frequently asymptomatic. These diseases include dermatitis herpetiformis,I,1 epidermolysis bull osa,1,4-10 pemphigus vulgarus 1,3,11--16 and bullous pemphi goid, 1 7 -22 As a family of diseases, they all have circulating antibodies to skin and mucous membrane basement mem brane. Antibodies and complement are bound to the base ment membrane of lesional and non-Iesional skin, However, the diseases differ by each having a unique component of the basement membrane as its antigen (T able I). The exceptions to this are that dermatitis herpeti formis does not have a circulating antibod/ and the anti gen in pemphigus vulgaris is the intercellular cement substance.12,13_ls The disease with the most severe ocular consequences is ocular cicatricial pemphigoid. 1
CLINICAL FEATURES OF OCULAR CICATRICIAL PEMPHIGOID
Ocular cicatricial pemphigoid (OCP) affects elderly patients, with a mean age at presentation of 58-69 years.23-26 Ocular involvement occurs in 66-77% of cases.23-2 7 In an ophthalmic series, skin lesions were pres ent in 9% of cases.2S Other mucous membrane involve ment included the mouth (15%), nose (12%) and oeosphagus (9% ).2S There is an association with HLA DQw7 (DQB 1 *030 1)28 and affected patients have a four fold increase in the prevalence of other autoimmune dis eases (p<0,01) -mainly rheumatoid arthritis but also systemic lupus erythematosus and polyarteritis nodosa.2s
The disease may be acute and associated with inflam mation, or chronic and not associated with inflammation, Further evidence for an autoimmune basis of the disease comes from the development of an animal model in rabbits, 45 The injection of a monoclonal antibody into basement membrane of conjunctival epithelium (MAb63) causes conjunctival inflammation, neutrophil infiltration and basement membrane deposition of IgG in a pattern similar to that seen in acute OCP.
Immunohistochemical studies25,33,40,44 have shown that the acute, ulcerative phase affects both the conjunctival epithelium and the substantia propria. The stromal changes in acute disease are characterised by a marked infiltration of neutrophils (Fig. 1) , macrophages, Langer hans/dendritic cells and T lymphocytes compared with normal controls. In addition, there is significantly increased expression of the major histocompatibility class II antigen (HLA-DR), there are equal numbers of CD4+ and CD8+ T-cells and 4-10% of the T-cells stain positive for interleukin 2 receptor, suggesting that they are acti vated33,40,44 (Fig. 2) . Staining for transforming growth fac tor-beta (TGF-�) is significantly increased.
The subacute phase of the disease is histologically similar to acute disease although the CD4+/CD8+ ratio drops to 0.4. The chronic phase is characterised by an infil tration with T lymphocytes (Fig. 3) , HLA-DR expressing cells and macrophages which are mildly increased in number. The CD4+/CD8+ ratio is 0.5.33 Mild to severe subepithelial fibrosis may be found in any of the three clinical phases.
For the conjunctival epithelium, the acute disease reveals marked infiltration with neutrophils and Langer hans cells. In chronic disease there is a similar cell profile to normal conjunctiva. T-cell infiltrate and upregulation of HLA-DR expression are not a feature of the epithelial disease. The epithelium may become thickened, metaplas tic and may keratinise at any phase. Overall, the popula tion of B-cells and plasma cells is no different to normal conjunctival epithelium or stroma at any stage of the disease. 33 Fibrosis results from the stimulation of fibroblasts, often by fibrogenic growth factors. When quiescent fibro blasts are stimulated to proliferate by these modulators, there is transient expression of proto-oncogenes, includ ing c-fos, c-myc and c-myb. These are a series of genes that are transducers of external growth factors and probably trigger the activation of genes that are required for pro liferation.46 Experimentally, c-fos and c-myc are expressed after application of TGF-�, platelet-derived growth factor (PDG F), tumour necrosis factor (TNF) and interleukin 1 (IL_1). 46, 47, 54 Conjunctival fibroblasts from patients with active cicatricial pemphigoid express c-myc in vitro. 48 This suggests that these fibroblasts have been stimulated
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with a growth factor similar to the effect produced by TGF-�, PDGF, TNF or IL-l. This is consistent with immu nohistochemical findings of raised levels of TGF-� in acute disease and of TGF-�, PDGF and fibroblast growth factor in subacute OCP. 33 The origin of these fibrogenic cytokines is unknown, but it is probable that they are pro duced by both acute and chronic inflammatory cell types.
CLINICAL RESPONSE TO SYSTEMIC DRUGS
Further insight into the mechanisms involved in fibrosis can be gleaned from the response to various drug treat ments in OCP. Both dapsone25,37,49,5o and cyclophospha mide25,29,5o have been shown to reduce inflammation and impair or halt the progression of the fibrosis compared with untreated controls. Dapsone is a sulphone and both inhibits the myelo peroxidase in polymorphonuclear leucocytes and stabil ises lysosomal membranes. This reduces the release of lysosomal enzymes.51 It also suppresses migration of neu trophils to extravascular sites through inhibition of the adhesion required for neutrophil recruitment.52 Therefore, a response to dapsone is mainly due to inhibition of neu trophil recruitment and function.
Moderate doses of cyclophosphamide suppress both B-cell and CD4+ and CD8+ T-cells. This leads to a sup pression of both T-cell-mediated and humoral responses.53 Therefore fibrosis may be inhibited by suppressing any or all of these cell lines. This points to a complex set of mech anisms that are involved in the aetiology of the fibrosis in OCP. This is further complicated by the number of growth factors demonstrated by immunohistochemistry.33 Further research is necessary to dissect in detail the mechanisms of cicatrisation in these inflammatory processes. This would be expected to lead to much more effective thera peutic regimes that may have fewer systemic side effects.
